In NASH patients with type 2 diabetes, it reduces hepatic steatosis, inflammation, and the serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels and improves the liver [125]. The gene discussed is GPT; the disease is type 2 diabetes mellitus.